IST raising $5m for cancer trial, ASX listing
Sydney-based Immune System Therapeutics (IST) will raise up to $5 million to help fund a global blood cancer trial and its upcoming ASX listing.
IST, an antibody technology company, will seek to place up to 100 million new shares at 0.05 cents per share.
The funds will be used to support a multinational phase IIb trial of cancer treatment candidate IST-1097 in multiple myeloma. This trial is due to commence next month. It will be conducted at The Alfred Hospital in Melbourne, as well as at up to nine other trial sites in the UK, Europe and the US.
IST-1097 binds to a protein found only on the surface of multiple myeloma cancer cells and not normal cells. It then directs a patient’s immune system to target and destroy the cancerous cells.
The latest trial will examine the efficacy of IST-1097 in combination with standard multiple myeloma therapies lenalidomide and dexamethasone, based on preclinical research suggesting that the former enhances the cell-killing activity of the IST antibody.
IST is meanwhile preparing for an ASX listing. The company is working with Peloton Capital on the listing, and expects to conduct the process in the third quarter.
Algae unlocks a more ethical way to grow cells
Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...
Oral drug shows promise for treating Barth syndrome
An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...
